Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anindya Chatterjee

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Journal of the Acoustical Society of America|June 3, 2018
Acoustics of Idakkā: An Indian snare drum with definite pitchKevin Jose, Anindya Chatterjee, Anurag Gupta
Oncotarget|July 10, 2015
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderAnindya Chatterjee, Joydeep Ghosh, Reuben Kapur
Scientific Reports|April 15, 2021
Data suggest COVID-19 affected numbers greatly exceeded detected numbers, in four European countries, as per a delayed SEIQR modelSankalp Tiwari, C P Vyasarayani, Anindya Chatterjee
Current Oncology (Toronto, Ont.)|February 24, 2023
Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United StatesRutika Mehta, Astra M Liepa, Shen Zheng, et al.
The Journal of Biological Chemistry|December 2, 2009
Activated Rac1 GTPase translocates protein phosphatase 5 to the cell membrane and stimulates phosphatase activity in vitroAnindya Chatterjee, Ling Wang, David L Armstrong, et al.
SAGE Open Medical Case Reports|November 23, 2020
Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four casesMan Yee Merl, Renee Moye, Anindya Chatterjee, et al.
Future Oncology (London, England)|May 17, 2023
Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancerAstra M Liepa, Zhanglin Lin Cui, Julie K Beyrer, et al.
BMC Cancer|January 19, 2023
Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference studyNeehar D Parikh, Allicia Girvan, Joshua Coulter, et al.
Frontiers in Oncology|August 29, 2024
Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging optionHaeseong Park, Samuel J Klempner, Joseph Chao, et al.
The Oncologist|May 26, 2021
Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III StudiesWasat Mansoor, Eric J Roeland, Aafia Chaudhry, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Journal of the Acoustical Society of America|June 3, 2018
Acoustics of Idakkā: An Indian snare drum with definite pitchKevin Jose, Anindya Chatterjee, Anurag Gupta
Oncotarget|July 10, 2015
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorderAnindya Chatterjee, Joydeep Ghosh, Reuben Kapur
Scientific Reports|April 15, 2021
Data suggest COVID-19 affected numbers greatly exceeded detected numbers, in four European countries, as per a delayed SEIQR modelSankalp Tiwari, C P Vyasarayani, Anindya Chatterjee
Current Oncology (Toronto, Ont.)|February 24, 2023
Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United StatesRutika Mehta, Astra M Liepa, Shen Zheng, et al.
The Journal of Biological Chemistry|December 2, 2009
Activated Rac1 GTPase translocates protein phosphatase 5 to the cell membrane and stimulates phosphatase activity in vitroAnindya Chatterjee, Ling Wang, David L Armstrong, et al.
SAGE Open Medical Case Reports|November 23, 2020
Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four casesMan Yee Merl, Renee Moye, Anindya Chatterjee, et al.
Future Oncology (London, England)|May 17, 2023
Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancerAstra M Liepa, Zhanglin Lin Cui, Julie K Beyrer, et al.
BMC Cancer|January 19, 2023
Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference studyNeehar D Parikh, Allicia Girvan, Joshua Coulter, et al.
Frontiers in Oncology|August 29, 2024
Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging optionHaeseong Park, Samuel J Klempner, Joseph Chao, et al.
The Oncologist|May 26, 2021
Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III StudiesWasat Mansoor, Eric J Roeland, Aafia Chaudhry, et al.
Pageof 3